Costs of Dose Escalation in RA Likely to Be Offset by Savings From Infliximab Biosimilars - The Center for Biosimilars

Costs of Dose Escalation in RA Likely to Be Offset by Savings From Infliximab Biosimilars  The Center for Biosimilars